Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value.
Analysis of cancer methylomes has dramatically changed our concept of the potential of diagnostic and prognostic methylation biomarkers in disease stratification. Through whole-genome methylation capture sequencing of triple-negative breast cancers (TNBCs) we recently identified differentially methylated regions with diagnostic and prognostic value that promise to stratify TNBCs for more personalized management.
Epigenetics Research Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia; These authors equally contributed to this work.
Clare
C
Stirzaker
Epigenetics Research Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; These authors equally contributed to this work.
Elena
E
Zotenko
Epigenetics Research Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia.
Susan J
SJ
Clark
Breast cancer; DNA methylation; DNA methylation biomarkers; prognostic biomarkers; triple-negative breast cancer